How is the Pandemic Affecting MI? The Chinese Experience

ST elevation acute myocardial infarction has high mortality and morbidity rates. It is normally treated with primary PCI. The whole system has established very effective protocols to minimize ischemic time from symptom onset to definite treatment in the cath lab. 

Recomendaciones de la ACC con el nuevo coronavirus

This study reports the experience in Hong Kong since January 2020, when all emergency protocols to contain the Covid-19 pandemic were activated.

This required suspending of all non-essential visits and adjusting services both for hospitalized and ambulatory patients. 

Between January 25 and February 10 2020, there were significant changes in assistance time compared against primary PCI in the same period one year earlier. 

The most affected was time between symptom onset and first medical contact. This depends mostly on patients, who will most likely wait at home for fear of catching Covid-19.


Read also Procedural Rescheduling Criteria in the Pandemic Era.


Historically, time from symptom onset to first medical contact is approximately 82 minutes, and it extended to 318 minutes during the pandemic.

We can scarcely understand the direct impact of this pandemic on the population’s health, let alone measure its indirect impact. 

To the extended onset to first contact time, we should add the extra time needed to identify patient epidemiology, contact history, symptoms, etc. 


Read also: ECS Guidelines for COVID-19 Management.


Finally, when primary PCI is indicated, we should also add extra time for safe patient transport, which involves time for all cath lab staff to wear protective gear. 

Original Title: Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China.

Reference: Chor-Cheung Frankie Tam et al. Circ Cardiovasc Qual Outcomes. 2020;13:e006631.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...